A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
As shown above, E. coli can grow with reducing agents such as formate, hydrogen, or lactate as electron donors, and nitrate, DMSO, or oxygen as acceptors. The larger the difference in midpoint potential between an oxidizing and reducing agent, the more energy is released when they react. Out of these compounds, the succinate/fumarate pair is unusual, as its midpoint potential is close to zero. Succinate can therefore be oxidized to fumarate if a strong oxidizing agent such as oxygen is available, or fumarate can be reduced to succinate using a strong reducing agent such as formate. These alternative reactions are catalyzed by succinate dehydrogenase and fumarate reductase, respectively. Some prokaryotes use redox pairs that have only a small difference in midpoint potential. For example, nitrifying bacteria such as Nitrobacter oxidize nitrite to nitrate, donating the electrons to oxygen. The small amount of energy released in this reaction is enough to pump protons and generate ATP, but not enough to produce NADH or NADPH directly for use in anabolism. This problem is solved by using a nitrite oxidoreductase to produce enough proton-motive force to run part of the electron transport chain in reverse, causing complex I to generate NADH. Prokaryotes control their use of these electron donors and acceptors by varying which enzymes are produced in response to environmental conditions. This flexibility is possible because different oxidases and reductases use the same ubiquinone pool.
== Course of the Wars of Independence (1810-1833) == Irreconcilable visions of how to reconstitute the lost unity led to a war that spread across the entire continent. At the end of 1810, the captive Ferdinand VII of Spain was recognized as a king subordinate to popular sovereignty by the Cortes of Cádiz and by several of the governing juntas, each in the territories under its control. The governing juntas across America wanted to reinstate Ferdinand VII as king subordinate and refused to accept the authority of the Council of Regency that was established with the dissolution of the Supreme and Central Governmental Junta of Spain and the Indies. In agreement on this, a military conflict arose between Royalists and Patriots over the unity or independence of the empire. In 1814 following the defeat of Napoleon and the restoration of the throne by the Treaty of Valençay, Ferdinand VII reimposed absolute monarchy through a coup d'état. He was able to defeat and repress the peninsular liberals, and abolished the liberal Constitution of Cadiz, although he could not defeat the revolutionaries in Spanish America, who resisted and formed their own national congresses. The Spanish navy had collapsed in the war against Napoleon, so therefore, in practice, it did not support the expeditionary forces who arrived in small groups. In 1820 Rafael del Riego led the Spanish army in revolt against absolutism, which began a period of Liberal rule known as the Trienio Liberal and ended the threat of invasion against the Río de la Plata.
In 1884 German chemist Eugen Baumann found that reduction of cystine with zinc gave monomer, which he named "cysteïne". The easy redox interconversion of cysteine and cystine has "provided more puzzles to protein chemists than any of the other amino acids".
Sources: en.wikipedia.org
In early stages of keratoconus, glasses or soft contact lenses can suffice to correct for the mild astigmatism. As the condition progresses, these may no longer provide the person with a satisfactory degree of visual acuity, and most practitioners will move to manage the condition with rigid contact lenses, known as rigid, gas-permeable, (RGP) lenses. RGP lenses provide a good level of visual correction, but do not arrest progression of the condition. In people with keratoconus, rigid contact lenses improve vision by means of tear fluid filling the gap between the irregular corneal surface and the smooth regular inner surface of the lens, thereby creating the effect of a smoother cornea. Many specialized types of contact lenses have been developed for keratoconus, and affected people may seek out both doctors specialized in conditions of the cornea, and contact lens fitters who have experience managing people with keratoconus. The irregular cone presents a challenge and the fitter will endeavor to produce a lens with the optimal contact, stability and steepness. Some trial-and-error fitting may prove necessary.
=== Experimental techniques === Many researchers around the world are investigating the pathogenesis of diabetes and beta-cell failure. Tools used to study beta-cell function are expanding rapidly with technology. For instance, transcriptomics have allowed researchers to comprehensively analyze gene transcription in beta-cells to look for genes linked to diabetes. Another technique to measure cellular function is cell imaging, notably with confocal or TIRF microscopy. Beta-cells can be modified to express a fluorophore that specifically labels insulin granules, which allows granule tracking and exocytosis measurement. Concerning calcium imaging, fluorescent dyes bind to calcium and allow in vitro imaging of calcium activity which correlates directly with insulin release. A final tool used in beta-cell research are in vivo experiments. Diabetes mellitus can be experimentally induced in vivo for research purposes by streptozotocin or alloxan, which are specifically toxic to beta cells. Mouse and rat models of diabetes also exist including ob/ob and db/db mice which are a type 2 diabetes model, and non-obese diabetic mice (NOD) which are a model for type 1 diabetes.
=== GABAergic signaling === One mechanism through which BDNF appears to maintain elevated levels of neuronal excitation is through preventing GABAergic signaling activities. While glutamate is the brain's major excitatory neurotransmitter and phosphorylation normally activates receptors, GABA is the brain's primary inhibitory neurotransmitter and phosphorylation of GABAA receptors tend to reduce their activity. Blockading BDNF signaling with a tyrosine kinase inhibitor or a PKC inhibitor in wild type mice produced significant reductions in spontaneous action potential frequencies that were mediated by an increase in the amplitude of GABAergic inhibitory postsynaptic currents (IPSC). Similar effects could be obtained in BDNF knockout mice, but these effects were reversed by local application of BDNF. This suggests BDNF increases excitatory synaptic signaling partly through the post-synaptic suppression of GABAergic signaling by activating PKC through its association with TrkB. Once activated, PKC can reduce the amplitude of IPSCs through to GABAA receptor phosphorylation and inhibition. In support of this putative mechanism, activation of PKCε leads to phosphorylation of N-ethylmaleimide-sensitive factor (NSF) at serine 460 and threonine 461, increasing its ATPase activity which downregulates GABAA receptor surface expression and subsequently attenuates inhibitory currents.
Sources: en.wikipedia.org
In April 2019, Collins began filming for her own reality series, Gemma Collins: Diva Forever. The series premiered in August 2019 on ITVBe. The pilot episode premiered to a total of 673,038 viewers, and was the most watched episode on ITVBe in that week. The same month, Collins began hosting a podcast on BBC Sounds, titled The Gemma Collins Podcast. It was also reported that Collins had signed a record deal with Universal Music Group, and was set to release a single with Naughty Boy after the pair met at the BRIT Awards 2019 and had been impressed by Collins' vocal ability, however plans for this never materialised. Diva Forever was subsequently renewed by ITV for a second series, but due to the COVID-19 pandemic, production was suspended. As a result, Collins filmed a new reality series, Gemma Collins: Diva on Lockdown, which featured Collins and her family in lockdown and aired between April and May 2020. In August 2020, Collins began hosting a second podcast on BBC Sounds entitled The Gemma Collins Love Lounge. In October 2020, Gemma Collins: Diva Forever & Ever premiered on ITVBe. In December 2020, Collins released a charity single, a cover of "Baby, It's Cold Outside" alongside her Celebrity Big Brother co-star Darren Day, with proceeds from the single going towards Rethink Mental Illness. The music video was released at the end of Gemma Collins: Diva for Xmas, which aired two days prior to the single's release and transpired to be the final episode of the show.
=== Collagen fibers === Type I collagen comprises approximately 85-95% of the organic matrix, providing the structural scaffold and tensile strength necessary for bone formation. These collagen fibers form a dense, highly cross-linked network that serves as the foundation for subsequent mineralization. The collagen molecules are arranged in layers that alternate parallel and orthogonal to the axis of stress loading, creating a sophisticated composite structure.
Loop type, in which the primary coolant is circulated through primary heat exchangers outside the reactor tank (but inside the biological shield due to radioactive 24Na in the primary coolant) Pool type, in which the primary heat exchangers and pumps are immersed in the reactor tank There are only two commercially operating breeder reactors as of 2017: the BN-600 reactor, at 560 MWe, and the BN-800 reactor, at 880 MWe. Both are Russian sodium-cooled reactors. The designs use liquid metal as the primary coolant, to transfer heat from the core to steam used to power the electricity generating turbines. FBRs cooled by liquid metals other than sodium have been built, some early FBRs such as Clementine used mercury, Lead-cooled fast reactor have also been constructed, as well as other experimental reactors using Lead-bismuth eutectic or NaK, a sodium-potassium alloy. Mercury and NaK have the advantage that they are liquids at room temperature, which is convenient for experimental rigs but less important for pilot or full-scale power stations, where their chemical toxicity and cost respectively leave them as less attractive options. The Soviet Union used lead–bismuth coolant in some naval reactors. BREST-OD-300 is a later Russian design that uses lead coolant. Its first concrete was poured in June 2021. The SVBR-100 design specifies lead-bismuth eutectic as its coolant. Three of the proposed generation IV reactor types use a fast-neutron spectrum:
== Production and composition == Dalbavancin is manufactured by fermentation of a selected Nonomuraea strain to generate the natural glycopeptide complex A-40926. This precursor is then selectively esterified at the carboxyl group of its sugar moiety, its peptidyl carboxyl group is amidated and the ester of the N-acylaminoglucuronic acid carboxyl group is saponified. The outcome is a compound mixture of two closely related structural families—A and B—that can be further subdivided into a total of five subtypes (see table below). At least ten different dalbavancin components have been described, of which the B0 component makes up around 80–98 wt%.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.